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TCRc-Chain Gene Rearrangement by GeneScan:
Incidence and Significance of Clonal Heterogeneity
in Se´zary Syndrome
Maria T. Fierro1, Renata Ponti1, Stefano Titli1, Lisa Bonello2, Alessandra Comessatti1, Mauro Novelli1,
Paolo Fava1, Paola Francia di Celle2, Pietro Quaglino1 and Maria Grazia Bernengo1
GeneScan (GS) analysis is a highly sensitive method for the early detection of cutaneous T-cell lymphoma
(CTCL) and allows the identification of clonal heterogeneity, defined as the coexistence of two or more different
T-cell clones in multiple samples from the same patient. We analyzed by GS the incidence and the significance
of long-lived oligoclonal expansions in multiple skin and blood samples from 24 Se´zary syndrome (SS) patients,
and tried to correlate them with the clinical outcome. A skin clonal heterogeneity with additional reproducible
TCRg-gene rearrangements (TCRg-GRs) was detected at diagnosis in 19/24 patients, 13 of whom had a constant
prevalence of pathological TCRg-GRs in both skin and blood (dominant clonal pattern). During follow-up, an
increase in oligoclones that were present at diagnosis or the appearance of new oligoclones was observed in 10
patients; all of them achieved a clinical response to treatment with extracorporeal photochemotherapy (ECP).
The TCRg pattern (homogeneity or heterogeneity) in the skin at diagnosis showed a relevant prognostic value,
and patients with an oligoclonal pattern had a significantly longer survival than those with a homogeneous
pattern. In conclusion, multiple-sample approach GS analysis allows the identification of clonal heterogeneity
and could also help in identifying SS patients with a potential higher response to therapy.
Journal of Investigative Dermatology (2010) 130, 2312–2319; doi:10.1038/jid.2010.97; published online 22 April 2010
INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous
group of lymphoid malignancies primarily arising into the
skin, in which the monoclonal tumor population emerges
frequently within a multiple subclone pattern (Ru¨bben et al.,
2004). Se´zary syndrome (SS), included among the aggressive
CTCLs in the new WHO-EORTC (World Health Organiza-
tion/European Organization for Research and Treatment of
Cancer) classification (Willemze et al., 2005), is a rare
primary epidermotropic CTCL characterized by erythroder-
ma, peripheral adenopathies, and blood involvement by
atypical lymphocytes with cerebriform nuclei. Even if it is
generally characterized by a poor prognosis with a 5-year
survival rate of 24% (Willemze et al., 2005), data in literature
show that median survival ranges from 2.5 up to 5 years.
Most patients die of infectious complications, as a result of
the severe disease-related immunosuppression, and to date
SS prognostic factors are yet not well defined (Bernengo et al.,
1998, 2007).
The demonstration of clonal TCR gene rearrangement (GR)
by PCR represents a common diagnostic marker for
lymphoproliferative disorders; in recent years, GeneScan
(GS) analysis with fluorescently labeled PCR primers and
capillary electrophoresis has been shown to be a highly
sensitive and specific method for the early detection of CTCLs
(Assaf et al., 2000; Lukowsky et al., 2002; Vega et al., 2002;
Sandberg et al., 2003; Costa et al., 2004; Greisser et al.,
2006; Klemke et al., 2006; Kuo et al., 2007; Ponti et al.,
2008; Thurber et al., 2007; Cozzio and French, 2008).
To date, only a few GS studies have been designed to ana-
lyze multiple skin and blood samples within the same
patient, to evaluate the specificity of TCRg-GR detection,
and to overcome bias in the interpretation of clonal pattern
because of a concomitant clonal heterogeneity background
(Vega et al., 2002; Thurber et al., 2007; Humme et al.,
2009).
Clonal heterogeneity, defined as the coexistence of two or
more different T-cell clones in distinct samples from the same
patient, has been recently described in CTCLs (Dippel et al.,
2001; Vega et al., 2002; Klemke et al., 2006; Ponti et al.,
2008; Cozzio and French, 2008). The distinction of clonal
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heterogeneity from homogeneity in multiple samples from
the same patient is probably underestimated, even if it could
be of prognostic relevance. In fact, it has been hypothesized
that clonal homogeneity in the absence of a reactive
background correlates with a high risk of disease progression
(Vega et al., 2002). Finally, to the best our knowledge, only
two studies have evaluated clonal heterogeneity in multiple
samples of CTCL patients (Ortonne et al., 2006; Ponti et al.,
2008), whereas the exclusion of pseudomonoclonality
(dominant PCR amplicons) by repeated independent PCR
analyses has been more stressed (Klemke et al., 2002, 2006;
Vega et al., 2002; Ponti et al., 2008; Cozzio and French,
2008). Circulating clonal T-cell populations have also been
described in infectious and autoimmune nonmalignant
conditions (Sakkas et al., 2002; Humme et al., 2009), such
as rheumatoid arthritis (Celis et al., 1997) and systemic
sclerosis (French et al., 2001), and in normal subjects
particularly if older than 65 years (Muche et al., 2003).
These preliminary data induced us to analyze by GS the
presence of a heterogeneity pattern of the TCRg-GR,
expressed as persistence of long-lived oligoclonal expanded
T cells in multiple skin and blood samples from SS patients
taken at different times during follow-up. The aim was to
better define the incidence and the significance of long-lived
oligoclonal expansions, and try to correlate them with the
clinical outcome and the therapy responsiveness. Actually,
the presence of clonal T-cell expansion in blood has been
shown to indicate responsiveness to extracorporeal photo-
chemotherapy (ECP) in patients with CTCL and systemic
sclerosis (French et al., 2001).
RESULTS
Rates of TCRc-GR in SS patients
Skin and blood samples of 24 SS patients were analyzed by
GS and compared with V-b-TCR (TCR-Vb) phenotypic
restriction (Table 1). An identical TCRg T-cell clone was
detected in both skin and blood from all 24 SS patients, and
also in the presence of a circulating Se´zary cell (SC) count of
o1,000 cellsmm3 (five patients). Conversely, a TCR-Vb
restriction was detected by flow cytometry and immunohis-
tochemistry in only 13/24 (54%) subjects. As each Vg family
primer was labeled with a different fluorescent dye, it was
possible to identify the Vg family used in each clonal TCRg-
GR: Vg1-8 was the most common Vg family (19/24, 79%),
followed by Vg10-11 (4/24, 17%) and Vg9 (4/24, 17%). Two
rearranged alleles with balanced biallelic amplification were
clearly observed in 9 (37.5%) of the 24 patients (Table 1).
GS analysis
It is possible to perform semiquantitative GR comparisons in
multiple samples, by measuring the peak heights, if PCR
amplification and capillary electrophoresis are simulta-
neously performed in all samples (Sprouse et al., 2000). In
any case, biallelic rearrangement can be difficult to
distinguish from clonal heterogeneity and repeated assays
on different samples may be necessary to clarify the pattern.
In brief, as shown in Table 1, we observed that true Vg1-8
biallelic TCRg-GRs showed identical peaks in all samples
(biallelic ratio ranging between 1.0 and 1.2), whereas in
biallelic TCRg-GRs involving different families (i.e., Vg1-8
and Vg10-11 V-family GR) the allelic amplification showed
little variation of peaks but always within a limited range
(patient 6, range 1.3–1.5 and patient 11, range 1.5–1.6); these
differences may be attributed to the competition between
specific primers in the PCR assay.
A balanced biallelic amplification resulting in similar peak
heights with a stable ‘‘allelic peak ratio’’ (range 1–1.5) was
found in nine patients. Conversely, an unstable and over 1.5
allelic peak ratio was observed during follow-up (range
1.9–3.1) in three other patients classified as heterogeneous
molecular pattern; the suspicion of a biallelic clonal
population was excluded on the basis of the imbalance
between the two peaks in multiple samples during follow-up
(patient 18, range 1.9–2.4; patient 19, range 1.9–3.5; and
patient 24, range 1.7–2.5).
Semiquantitative evaluation of clonal heterogeneity
An accurate semiquantitative comparison of amplicons
allows the estimation of clonal heterogeneity, considered as
the relative amount of T-cell clones among the oligo/
polyclonal background (Sprouse et al., 2000). The clonal
population was compared with the most expanded oligoclo-
nal TCRg-GR and the relation was expressed as the peak
height ratio between the pathological and the major reactive
clone.
A patient was considered to have a clonal heterogeneity
when a common TCRg-GR was concomitant to additional
long-lived reproducible TCRg-GRs or a transient oligoclonal
T-cell expansion in skin and blood samples. On the other
hand, a patient was considered to have a clonal homogeneity
when the pathological TCRg-GR was present in the skin
without a concomitant polyclonal or oligoclonal reactive
background. The homogeneity and heterogeneity molecular
pattern classification (Tables 1 and 2) refers to the skin at
diagnosis time, as blood pattern was more variable because
of the frequent finding of additional transient oligoclones.
Clonal homogeneity in the skin was detected at diagnosis in
5/24 patients (Tables 1 and 2); two of these patients showed
the presence of oligoclones in the blood. Skin clonal
heterogeneity with additional reproducible TCRg-GRs was
noted in the remaining 19 patients, 13 of whom had a
constant prevalence of pathological TCRg-GRs in both skin
and blood (dominant clonal pattern; Figure 1a and b).
Identification of common TCRg-GRs was even more difficult
in the remaining six patients, because of a nondominant
clonal pattern in skin or blood at diagnosis, with a
coexistence of at least two different prominent peaks
(Table 1). In these cases, identity of the pathological TCRg-
GR was confirmed by comparing the peak ratio in skin and
blood samples (Figure 2) and, in four cases, by repeating GS
analysis on the sorted circulating TCRg-Vbþ or
CD4þCD26 population (Figure 3).
The entity of the heterogeneity could vary into a spectrum
(Table 1) ranging from small-sized additional nonshared and
reproducible GRs (þ ) to several stable long-lived oligoclonal
GRs in skin or blood (þ þ ).
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TCRg-GR Clonal Heterogeneity in SS
Comparison between skin and blood
Semiquantitative GS data allowed us to show a major clonal
involvement in blood compared with skin in all cases except
one at diagnosis.
The 13 patients with a constant skin/blood dominant
pattern always showed in the skin a peak height ratio
between the pathological and the major reactive clone 42
(2.1–50.4). Conversely, in the six unclear cases due to a
nondominant pattern in skin (3 patients) or blood (3 patients),
the comparison between the two districts allowed the
identification of the pathological clone (Figure 2).
Correlation between clonal pattern and hematological/
histopathological features
The group of patients characterized by a homogeneous
molecular pattern showed a higher number of circulating SCs
(median 7,514mm3; range 6,581–50,380) than those
with clonal heterogeneity (median 3,625mm3; range:
234–30,863). The five patients with a homogeneous pattern
showed a dense infiltrate involving the deep dermis and basal
and/or suprabasal epidermotropism with prominent cell
atypia (score 2 or 3); on the other hand, the majority of
patients (14/19) with a heterogeneous pattern had a mild
perivascular superficial infiltrate and a lower degree of
epidermotropism with mild atypia (score 1). There was a
significant correlation between the homogeneous pattern and
the histological features (Fisher’s test: P¼0.005). In all, 13
cases showed a TCR-Vb restriction detectable in immuno-
histochemistry: the three patients with a homogenous
molecular pattern expressed the TCR-Vb on 490% atypical
CD4þ lymphocytes in both derma and epidermis; con-
versely, the 10 patients with a heterogeneous molecular
Table 2. Molecular pattern modifications during follow-up and correlation with the clinical course
No. of skin/PBL oligoclones1 Follow-up
No. Skin pattern Stable Transient Therapy Length (mo)
Clinical
outcome
TCRc-GR
changes in PBL
1 HE++ 2/1 1/3 MoAb CD52+ECP 128 CR I
2 HE++ 3/3 0/P ECP 42 SD NE
3 HE+ 2/2 1/2 ECP+MoAb CD52+FAMP 22 SD NC
4 HO 0/0 0/P FAMP+ECP 20 PD NE
5 HE++ 2/1 2/4 MoAb CD52+ECP 26 PR D
6 HO 0/0 0/3$ FAMP+ECP+CHL 16 PD NE
7 HE+ 2/2 1/2 ECP+BEX 45 PR I
8 HE+ 1/P 0/2$ ECP+MoAb CD52 25 SD NC
9 HE++ 1/1 5/2 ECP 90 PR I
10 HO 0/0 0/1$ MoAb CD52+ECP 20 PD D
11 HE++ 1/1 1/P ECP+MTX 25 PR NC
12 HE++ 2/2 3/5 FAMP+CHL+MoAb CD52 92 CR I
13 HE++ 1/1 2/P ECP+MoAb CD52 34 PR I
14 HE++ 2/2 2/5 NONE 0 NE NE
15 HE++ 3/3 P/1 ECP 50 PR I
16 HO 0/0 0/P CHL+MoAb CD52 34 SD NC
17 HE+ 1/1 P/3 CHL+MTX 16 PD NC
18 HE++ 2/2 2/1 ECP+MoAb CD52 44 PR I
19 HE++ 2/2 P/P ECP 26 SD D
20 HE+ P/P P/P FAMP+ECP+BEX+MoAb CD52 38 SD NC
21 HE++ 1/1 1/P ECP+MoAb CD52 84 PR I
22 HO 0/0 0/1$ MoAb CD52 22 PD D
23 HE++ 3/3 4/3 ECP 8 PR I
24 HE++ 4/4 0/P FAMP+ECP+CHL 85 PR I
BEX, bexarotene; CHL, chlorambucil; CR, complete response; D, decrease in oligoclonal GRs; ECP, extracorporeal photochemotherapy; FAMP, fludarabine
monophosphate; HE, clonal heterogeneity; HO, clonal homogeneity; I, increase in PBL oligoclonal GRs; MoAb CD52, alemtuzumab; MTX, methotrexate;
NC, no change in oligoclonal pattern; NE, not evaluable (lost at follow-up); NONE, no therapy (lost at follow-up); P, polyclonal; PBL, peripheral blood
lymphocyte; PD, progressive disease; PR, partial response; SD, stable disease; TCRg-GR, TCRg gene rearrangement.
$Oligoclonal expansions detected only in PBL during follow-up.
1Stable is long-lived GR coexisting in skin and blood, and transient is transitory GR detectable either in skin or blood.
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pattern expressed TCR-Vb on a variable proportion of CD4þ
atypical lymphocytes (Supplementary Figure S1 online).
Correlation between clonal pattern and clinical outcome during
follow-up
Multiple blood samples taken during follow-up (median
length 29 months; range 8–128) were available in 20/24
patients; four had only a single evaluation and one (patient
14) was lost at follow-up. In 10 patients we could observe an
oligoclone peak height increase in blood or the appearance
of new oligoclones (Table 2 and Figures 1c and d and 4). In
patients who were first treated with low-dose alemtuzumab
(patients 1, 13, and 18; median cumulative dose 73mg, range
13–137) because of a high tumor burden, the massive
destruction of atypical lymphocytes allowed reactive clones
to appear immediately after alemtuzumab treatment and to
progressively grow during ECP (Figure 4a). ECP was under-
taken as first therapy in patients with a lower amount of
circulating SCs; it is interesting to underline that oligoclone
peak height increase occurred in all patients except one
during treatment with ECP (Figure 4b). All the patients with
such peak height increase achieved a clinical response,
consisting of a partial response in eight cases and a complete
response in the remaining two. Of the remaining 10 patients,
4 showed a decrease in the amount of oligoclonal GRs, and
6 had a stable molecular pattern. All the four patients who
experienced a reduction in the amount of oligoclonal GRs
died within 2 years. Molecular pattern in the skin was
evaluated in univariate analysis according to the disease
course: SS survival was significantly higher (P¼0.0051) in
patients characterized by clonal heterogeneity (median
survival 7 years; range 0.5–10.7 years) than in those with
clonal homogeneity (median 1.75 years; range 1.3–2.8). No
statistical differences were found among patients with weak
(þ ) and strong (þ þ ) oligoclonal pattern.
DISCUSSION
Limited heterogeneity of the TCRg makes it more suitable
than the b-locus for the determination of clonality by PCR,
but requires high-resolution electrophoresis to separate PCR
products by denaturing gradient gel electrophoresis, hetero-
duplex analysis, or GS; all these are highly sensitive methods
to evaluate the lymphoid clonality in CTCL, and the
sensitivity is still enhanced if a multiple-sample approach is
applied (Wood et al., 1994; Theodorou et al., 1995; Sprouse
et al., 2000; Lukowsky et al., 2002; Ponti et al., 2005, 2008).
In our study, GS sensitivity ranges from 0.5 to 5% in the
identification of an unknown clonal population (Ponti et al.,
2008). Our two primers set GS PCR assay cover all possible
Vg and Jg combinations, similar to the BIOMED-2 recently
standardized assay, which was applied to the analysis of
TCRg-GR in CTCL in two different studies (Sandberg et al.,
2003; Morgan et al., 2006).
For a long time, TCR monoclonality has been considered a
dogma in the field of lymphomas: Ru¨bben et al. (2004)
suggested, using microsatellite DNA studies, that tumor
population may arise from multiple subclones and show a
multilineage progression. Oligoclonal cytogenetic abnormal-
ities have also been described in mycosis fungoides (MF).
Moreover, a marked reduction in the T-cell repertoire
complexity has been described in the peripheral blood of
advanced-stage CTCL using a sensitive b-variable comple-
mentarity-determining region 3 spectratyping approach
(Yawalkar et al., 2003). Taken together, these studies suggest
that CTCLs are not only a mere expansion of a pathologic
Figure 1. Se´zary syndrome (SS) patient 18 with heterogeneous pattern. (a, b)
Skin and blood at diagnosis; and (c, d) skin and blood during follow-up
(2 years later). Filled peak¼ pathological clone (296 bp, VIgJg family).
*Reactive oligoclones present at diagnosis and stable during follow-up.
**Onset of new oligoclones during treatment.
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T-cell clone over the background, but also deeply involve the
nonmalignant compartment. With the development of highly
sensitive capillary electrophoresis methods, the reports of
molecular clonal heterogeneity in CTCL also became more
frequent (Vega et al., 2002; Klemke et al., 2006), but only
with the onset of a multiple-sample approach the existence of
heterogeneous molecular pattern has been accepted by the
scientific community (Vega et al., 2002; Thurber et al., 2007;
Humme et al., 2009). The possibility that persistent and
variable clonal GRs or nonshared multiple T-cell clones may
coexist in the same patient raises new questions on their
clinical significance, as they may reflect a mixture of
neoplastic and reactive T-cell clones or the selection of a
newly arising clone (Yawalkar et al., 2003; Klemke et al.,
2006; Cozzio and French, 2008). The temporary dominance
of transient clones and the problem of pseudomonoclonality
on a single sample could lead to an incorrect identification of
the pathological population, unless results are analyzed with
repeated PCR runs on the same sample, as was recently
stressed by some researchers (Dippel et al., 2001; Klemke
et al., 2006). Moreover, the importance of compa-
rison between multiple skin and blood samples has been
underlined (Thurber et al., 2007; Ponti et al., 2008; Humme
et al., 2009).
The cutaneous district is known to be colonized by
selected skin-homing T-cell populations and could therefore
more frequently show an oligoclonal than a polyclonal
pattern. In our previous paper we stated that GS method
coupled with a multiple-sample approach is the most
appropriate technique for CTCL diagnosis, particularly in
the early stage of the disease, and that clonal heterogeneity is
a frequent finding in MF (48%) and SS (80%). In addition,
using a multiple skin/blood sample approach, the positive
predictive value in nondiagnostic CTCL samples yielded
90%, whereas no false-negative results were observed (Ponti
et al., 2008). These figures are higher than those reported by
Vega et al. (2002), who obtained approximately 30%
heterogeneity in MF patients. Ortonne et al. (2006) also
reported the coexistence of malignant and nonmalignant
circulating clones in SS using an immunoscopy method and
distinguishing the nonmalignant circulating clones from the
malignant ones because of the lack of CD158k expression on
their surface.
In this study we focused our attention on SS and we
carried out a systematic analysis on multiple skin and blood
samples, following the clinical course of the disease. In SS
skin samples, clonal heterogeneity (19/24 patients) was more
frequent than homogeneity; as a consequence, the distinction
between biallelic rearrangements (nine patients) and highly
expanded oligoclones was a challenge, and only the
availability of multiple samples and the comparison with
blood allowed to clarify each single case. In our experience,
a close peripheral blood lymphocyte monitoring using GS
allows the pathological clone to clearly emerge over the
background in also those patients who have a low SC count.
SS is characterized by a poor prognosis, with a median
survival ranging from 2.5 up to 5 years and a 5-year survival
of 24% (Willemze et al., 2005). SS prognostic factors are not
well defined, although the majority of papers agree that the
extent of peripheral blood involvement constitutes one of the
most relevant parameters associated with the disease course.
In our experience, we observed a 5-year survival rate of
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Figure 2. Se´zary syndrome (SS) patient 14. (a) Skin: heterogeneous pattern in
skin biopsy at diagnosis with hidden pathological clone (251 bp, VIIgJg
family); the comparison between skin (a) and blood (b) allows a correct
identification. *Pathological clone; **reactive oligoclone.
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Figure 3. Se´zary syndrome (SS) patient 24. (a) Unsorted peripheral blood
lymphocyte (PBL) showing two emerging peaks from the background. (b)
Sorted TCR-Vb17 cells; only the reactive oligoclone is evident. (c) Sorted
CD4þCD26TCR-Vb17þ cells showing the pathological 269VIg clone.
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Figure 4. Molecular pattern modifications during treatment. (a) Patient 1
treated with alemtuzumab followed by extracorporeal photochemotherapy
(ECP). (b) Patient 9 treated with ECP alone.
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55.8% in patients with a low or moderate blood involvement
(SC p2,600mm3) and only 11.6% in patients with higher
levels (SC42,600mm3) (Bernengo et al., 1998). In this study
we show that patients with an oligoclonal pattern in the skin
at diagnosis have a longer survival and that the increase of the
peak/height or the appearance of new oligoclones in the
blood during treatment is associated with a higher response
to therapy. Obviously, the number of patients is limited
because of the rarity of the disease and therefore caution is
mandatory; nevertheless, these data, coupled with the
frequent observation of oligoclone expansion during ECP in
responding patients, point to suppose that ECP may induce
the expansion of selected reactive T-cell clones as reported in
other pathologic conditions (French et al., 2001; French and
Rook, 2002). In conclusion, clonal heterogeneity is a frequent
condition in SS patients and requires high-resolution techni-
ques such as GS for a correct identification of the
pathological population. GS analysis is actually the simplest
and a quick method for TCRg-GR studies, but it must be
coupled with a multiple-sample approach to avoid the risk of
false negatives or mistakes in clonal identification, especially
in the early disease phase or in cases with low blood
involvement. We suggest that the correct diagnostic approach
at diagnosis is represented by comparison between two skin
biopsies from different sites and one blood sample. Multiple-
sample GS analysis could also constitute a useful tool to
identify patients with a potentially higher response to therapy,
particularly ECP. As recently suggested, the application of the
new standardized BIOMED2-GS TCRg-GR protocol (Goeldel
et al., 2010) and a multiple-sample approach could give
further insights into the significance of clonal heterogeneity.
MATERIALS AND METHODS
Patients and biopsy specimens
This study was performed in compliance with the principles of good
clinical practice and according to the Declaration of Helsinki
Principles. The study protocol was approved by the ethical
committee of Turin University. All patients were included after
providing their written informed consent. The diagnosis of SS was
made according to the standard clinical and immunopathological
findings (Willemze et al., 1997; Vonderheid and Bernengo, 2003).
The SS diagnostic criteria included: (1) erytroderma and lymphade-
nopathies; (2) peripheral blood involvement by circulating Se´zary
cells; and (3) cutaneous biopsy-proven CTCL. Peripheral blood
immunophenotype and clonal TCR-Vb expression was also assessed.
SS cells were defined using TCR-Vb expression or lack of CD26
(Bernengo et al., 2001).
The biopsy specimens were divided into two pieces: one was
used for histological evaluation on paraffin-embedded sections, and
the other was cryopreserved for immunohistochemical staining and
for TCRg clonality studies. Immunohistochemical staining was
performed in all cases by the standard streptavidin-biotin-peroxidase
method (LSAB2plus Kit; Dako, Glostrup, Denmark), using mono-
clonal antibodies against the T-cell lineage antigens.
From a histological point of view, the extent of the infiltrate, the
epidermotropism, and cell atypia were graded according to previous
reported criteria (Guitart et al., 2001; Ponti et al., 2005). The density
of the infiltrate was scored as follows: 1¼mild perivascular infiltrate;
2¼ band-like lymphoid infiltrate; and 3¼ dense infiltrate with
extension into the deep reticular dermis. The epidermotropism was
scored as follows: 1¼ focal basal epidermotropism; 2¼ extensive
basal epidermotropism or Pautrier’s microabscesses; and
3¼ extensive pagetoid epidermotropism with more lymphocytes
than keratinocytes in the epidermis. Cytological atypia was scored
as: 1¼mild; 2¼moderate; and 3¼ uniformly atypical or trans-
formed lymphoid infiltrate.
GS TCRc-GR analysis
Genomic DNA was extracted from 20 (20 mm) Tissue-Tek OCT
embedding compound cryopreserved tissue sections and from
peripheral blood lymphocytes using a QIAgen tissue kit (QIAamp
DNA Mini Kit; Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s instruction.
TCRg-GR was studied by GS capillary electrophoresis analysis.
The same primers, consensus and specific for each Vg or Jg segment
family, and PCR condition was performed as previously reported
(Ponti et al., 2008). In brief six PCRs, including one Vg family
fluorescent primer (V1-8–FAM or V9-HEX or V10-11-NED) plus a Jg
primer (Jg1/2 or JgP1/2), were performed; two mixtures of PCR
products, labeled PCR products, were subjected to GS on the ABI 310
PRISM CE sequencer (PE Applied Biosystems; Weiterstadt, Germany)
and analyzed on the same plot using the GeneScan Software (Applied
Biosystems). In all cases, two separate PCR assays were performed as
previously recommended (Dippel et al., 1999; Klemke et al., 2002,
2006; Cozzio and French, 2008; Ponti et al., 2008). Moreover, in the
second PCR run, each sample was processed together with all the
previous specimens from the same patient to allow the semiquanti-
tative comparison of clonal population during follow-up. Skin and
blood samples comparison was performed in all patients.
Statistical analysis
Overall survival was calculated from SS diagnosis time to the date of
death or last check-up for all patients. In the univariate analyses, the
product-limit estimates were derived using the Kaplan–Meier method
(Kaplan and Meier, 1958), and the statistical comparisons were
carried out using the log-rank Mantel–Cox test (Mantel, 1966; Cox,
1972). Fisher’s exact probability test was used for cross-table
comparisons. Data were processed using the SPSS 15.0 software
package (SPSS, Chicago, IL).
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